(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
BHP liable for 2015 Brazil mine disaster: UK court - 2South America's Memorable Destinations: A Movement Guide
- 3Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
- 4The largest sun of 2026 rises today as Earth draws closest to our parent star
- 5Dutch police probe a small blast outside a pro-Israel Christian center
- Instructions to Guarantee Kids Foster Solid Dental Propensities
- China Just Got Another Cheap EV America Would Love to Have
- Instructions to Pick the Right Toothpaste for Your Dental Requirements
- Solar storms can trigger auroras on Earth. This star’s explosion could destroy a planet’s atmosphere
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- NASA's Artemis 2 moon launch may be visible from Florida and southern Georgia today. Here's when to look
- Pick Your #1 breakfast food
- Addressing sleep apnea early might decrease chances of developing Parkinson's disease
- 75% of US adults may meet criteria for obesity under new definition, study finds
